- Solvay SA
- Fournier Pharma
- UCB SA
- Pierre Fabre Group
- Bristol-Myers Squibb Co.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline PLC
- Boehringer Ingelheim Fremont Inc.
- Genfit SA
- UCB Group
- Merck KGaA
- Servier SA
- Cypress Bioscience Inc.
- Forest Laboratories Inc.
- H. Lundbeck AS
- Altana AG
- Solvay agrees to acquire Fournier
- UCB buys Celltech for £1.53bn in cash
- bioMerieux, Pierre Fabre merge; then part ways
- BMS, Pierre Fabre Medicament SA develop cancer therapy; ended
- Merck, Pierre Fabre Medicament sign oncology deal
- Elf Aquitaine's Sanofi merges with Synthlabo
- Sanofi-Synthélabo closes takeover of Aventis
- BMS joins Sterling, Sanofi on heart projects; agreement later revised
- Pfizer licenses Coley's ProMune in potential $515mm deal
- Genfit, Pierre Fabre sign new cardiovascular deal
- Cypress Bioscience licenses bioMerieux-Pierre Fabre drug
- Cypress licenses milnacipran rights to Forest Laboratories
- Merck, Lundbeck terminate sleep drug license deal
- Aventis co-promotes Byk Gulden's Ciclesonide in US
- Altana, Pharmacia develop and market roflumilast; deal ends
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.